Clinical or ATPase domain mutations in ABCD4 disrupt the interaction between the vitamin B12-trafficking proteins ABCD4 and LMBD1

  1. Matthias R. Baumgartner7
  1. 1 University Childrens Hospital, Switzerland;
  2. 2 CNRS Univ Paris Descartes, France;
  3. 3 UMR Inserm UL U954, Switzerland;
  4. 4 University Childrens Hospital Queen Fabiola, Belgium;
  5. 5 CNRS/Universite Paris Descartes, France;
  6. 6 University Descartes, France;
  7. 7 University of Zurich, Switzerland
  1. * Corresponding author; email: sean.froese{at}kispi.uzh.ch
  1. Author contributions: DC, BF, DSF and MRB conceived the idea of the project. VF designed the research together with PB, CS, BG, DSF and MRB. VF performed most of the experiments. Experimental work was also carried out by PB, CS, DC, and BB. CDL provided clinical data. NP and BG generated the homology model. SL and TS performed the experiments to determine the cblJ defect in the patient. VF and DSF wrote the paper with contributions from the other authors. All authors analyzed the results and approved the final version of the manuscript.

Abstract

Vitamin B12 (cobalamin, Cbl), in the cofactor forms methyl-Cbl and adenosyl-Cbl, is required for the function of the essential enzymes methionine synthase and methylmalonyl-CoA mutase, respectively. Cbl enters mammalian cells by receptor-mediated endocytosis of protein-bound Cbl followed by lysosomal export of free Cbl to the cytosol, and further processing to these cofactor forms. The integral membrane proteins LMBD1 and ABCD4 are required for lysosomal release of Cbl, and mutations in the genes LMBRD1 and ABCD4 result in the cobalamin metabolism disorders cblF and cblJ. We report a new (fifth) patient with the cblJ disorder, who presented at 7 days of age with poor feeding, hypotonia, methylmalonic aciduria, and elevated plasma homocysteine and harbored the mutations c.1667_1668delAG [p.Glu556Glyfs*27] and c.1295G>A [p.Arg432Gln] in the ABCD4 gene. Cbl cofactor forms are decreased in fibroblasts from this patient, but could be rescued by over-expression of either ABCD4 or, unexpectedly, LMBD1. Utilizing a sensitive live-cell FRET assay, we demonstrated selective interaction between ABCD4 and LMBD1, and decreased interaction when ABCD4 harbored the patient mutations p.Arg432Gln or p.Asn141Lys, or artificial mutations disrupting the ATPase domain. Finally, we showed that ABCD4 lysosomal targeting depends on co-expression of, and interaction with, LMBD1. These data broaden the patient and mutation spectrum of cblJ deficiency, establish a sensitive live-cell assay to detect the LMBD1-ABCD4 interaction, and confirm the importance of this interaction for proper intracellular targeting of ABCD4 and cobalamin cofactor synthesis.

  • Received March 6, 2017.
  • Accepted June 1, 2017.

This Article

  1. jbc.M117.784819.
  1. Supplemental Data
  2. All Versions of this Article:
    1. M117.784819v1
    2. 292/28/11980 (most recent)

Article Usage Stats

ORCID

Submit your work to JBC.

You'll be in good company.